CCND1 and breast cancer: For example, in Roberts et al.[51], we showed that the CyclinD1 dependent TgMMTV-Neu tumors are sensitive to a CDK4/6 inhibitor, while the basal-like TgC3(1)-Tag tumors were not; these studies are consistent with findings coming from human clinical trials of luminal/ER + breast cancers, which were generally noted to be sensitive to a CDK4/6 inhibitor [54].